Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 13.30 |
|---|---|
| 52-week range | 11.91 – 17.73 |
| Return, 1 month / 3 months | +6.6% / −6.0% |
| Return, 1 year / 3 years | −22.7% / +41.3% |
| Trend | Below its 200-day average |
| RSI (14) | 66 |
| Volatility (1 year) | 31.2% |
| Worst drawdown (1 year) | -30.6% |
| Average daily value traded | 1.38M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eckert & Ziegler Strahlen- und Medizintechnik AG is a German medical technology company that works with radioisotopes for healthcare and industry. It makes radiopharmaceuticals and radioactive sources used in cancer treatment, including brachytherapy products, and supplies equipment and services for nuclear medicine and radiochemistry. Its customers include hospitals, clinics, research institutions and industrial users, and the company is based in Berlin.
On this site Eckert & Ziegler Strahlen- und Medizintechnik AG appears as a stock on the XETRA Stock Exchange (Germany), code EUZ, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 13.30 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 426 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.7% and over the last three months it fell 6.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 34 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -6.9% | ||
| From 52-week high | -24.7% | ||
| Momentum | 32 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.0% | ||
| 6-month return | -10.1% | ||
| 12-month return, skipping the last month | -27.5% | ||
| Stability (higher is calmer) | 57 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.6% | ||
| Liquidity | 75 · Strong | Trades actively. | |
| Average daily value traded | 1.38M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.0% |
|---|---|
| 1 month | +6.6% |
| 3 months | −6.0% |
| 6 months | −10.1% |
| 1 year | −22.7% |
| 3 years | +41.3% |
| 5 years | −61.5% |
Signals
| 50-day / 200-day average | 12.67 / 14.28 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.35 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 25 Jun 2026 | EUR 0.2200 |
| 19 Jun 2025 | EUR 0.5000 |
| 27 Jun 2024 | EUR 0.0500 |
| 29 May 2024 | EUR 1.5000 |
| 8 Jun 2023 | EUR 0.5000 |
| 2 Jun 2022 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.